

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 221/14, A61K 31/435		A1	(11) International Publication Number: WO 94/02466
			(43) International Publication Date: 3 February 1994 (03.02.94)
(21) International Application Number: PCT/US93/06771 (22) International Filing Date: 22 July 1993 (22.07.93) (30) Priority data: 07/919,227 27 July 1992 (27.07.92) US 08/016,553 11 February 1993 (11.02.93) US (71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors: KALTENBACH, Robert, Frank, III ; 2004 Walmsley Drive, Wilmington, DE 19808 (US). SUN, Jung-Hui ; 149 Aintree Lane, Hockessin, DE 19707 (US). CHERNEY, Robert, Joseph ; 104 Bridleshire Court, Newark, DE 19711 (US). SEITZ, Steven, Paul ; 333 Haverford Place, Swarthmore, PA 19081 (US).		(74) Agents: FERGUSON, Blair, Q. et al.; The du Pont Merck Pharmaceutical Company, Legal/Patents Records Center, 1007 Market Street, Wilmington, DE 19898 (US). (81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: UNSYMMETRICAL MONO-3-NITRO BIS-NAPHTHALIMIDES AS ANTICANCER AGENTS			
<div style="text-align: center;"> <p>(I)</p> </div>			
<div style="text-align: right;"> Atty. Docket No. 01414/1/US Serial No.10/722,104 Becker et al. Reference 15 </div>			
(57) Abstract <p>This invention relates to unsymmetrical mono-3-nitro bis-naphthalimides of formula (I) including (R,R)-2-[2-((2-(1,3-dioxo-1H-benz[de]isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-methylethyl]-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-dione, processes for their preparation, pharmaceutical compositions containing them, and methods of using them to treat cancer, particularly solid tumor carcinomas, in mammals.</p>			

OFFICIAL AVAILABLE COPY

LV 227 000 007 US

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

5

TITLE

Unsymmetrical Mono-3-Nitro Bis-Naphthalimides as
Anticancer Agents

10

Cross Reference to Earlier Filed Application


This application is a continuation-in-part
application of U.S. Patent Application SN 07/919,227,
filed July 27, 1992.

15

FIELD OF THE INVENTION

This invention relates to unsymmetrical mono-3-
nitro bis-naphthalimides of formula

20



25

including (R,R)-2-[2-[2-((2-(1,3-dioxo-1H-
benz[de]isoquinolin-2-(3H)-yl)-propylamino)ethylamino]-
1-methylethyl)-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione, processes for their preparation, pharmaceutical
compositions containing them, and methods of using them
to treat cancer, particularly solid tumor carcinomas, in
mammals.


30

BACKGROUND OF THE INVENTION

Harnisch et al., U.S. Patent 4,841,052 issued June 20, 1989 describe naphthalic acid imides useful as charge-regulating substances in electrophotographic toners.

5

Brana et al., U.S. Patent 4,874,863 issued October 17, 1989 discloses anticancer compounds of the formula:



10

wherein x^1 , x^2 , x^3 and x^4 are identical or different and are each H, NO_2 , NH_2 , $\text{C}_1\text{-C}_6$ -alkylamino, di- $\text{C}_1\text{-C}_6$ -alkylamino, OH, $\text{C}_1\text{-C}_6$ -alkoxy, halogen, trihalomethyl, $\text{C}_1\text{-C}_6$ alkyl, formyl, $\text{C}_1\text{-C}_6$ -alkylcarbonyl, ureyl, $\text{C}_1\text{-C}_6$ -alkylureyl and R is a straight chain or branched $\text{C}_4\text{-C}_{10}$ -alkylene which is interrupted at one or two points in the chain by a secondary or tertiary amino group, where 2 nitrogen atoms may additionally be bonded to one another by an alkylene group, or a salt with a physiologically tolerated acid.

15

20

25

Brana et al., U.S. Patent 4,874,863 does not specifically disclose the compounds of the present invention.

30


The compounds of the present invention have unexpectedly increased water solubility compared to certain compounds specifically disclosed in U.S. Patent 4,874,863. This is an important advantage, since the less soluble compounds present serious problems when

trying to formulate such compounds into a dosage form suitable for human use.

In addition the compounds of the present invention exhibit unexpected superior antitumor activity relative to the compounds specifically disclosed by Brana et al.

DETAILED DESCRIPTION OF THE INVENTION

There is provided by this invention bis-naphthalimide compounds having the formula (i):



(i)

or enantiomeric or diastereomeric forms thereof, or mixtures of enantiomeric or diastereomeric forms thereof, or pharmaceutically acceptable salts thereof, wherein:

R^{11} , R^{12} , R^3 , R^4 , R^5 , and R^6 , independently, are H or CH_3 .

Preferred compounds of the present invention include those compounds of formula (i) wherein:

R^{11} and R^6 are CH_3 ; and

R^{12} , R^3 , R^4 , and R^5 are H.

The specifically preferred compounds of the present invention are the following, and pharmaceutically acceptable salts thereof:


- 5 (R,R)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione;
- 10 (S,S)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione;
- 15 (racemate + meso)-2-{2-[2-((2-(1,3-Dioxo-1H-
benz[de]-isoquinolin-2-(3H)-yl)-
propylamino))ethylamino]-1-methylethyl}-5-nitro-1H-
benz[de]isoquinolin-1,3-(2H)-dione; and
- 20 (meso)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione.

25

Also provided by this invention are processes for the preparation of the compounds of formula (i), pharmaceutical compositions containing the compounds of formula (i), and methods of using these compounds for
30 the treatment of cancer, particularly solid tumor carcinomas, in a mammal.

The present invention includes methods of preparing a compound having the formula (i):

35



(i)


or enantiomeric or diastereomeric forms thereof, or
 5 mixtures of enantiomeric or diastereomeric forms
 thereof, and pharmaceutically acceptable salts thereof,
 wherein:

R¹¹, R¹², R³, R⁴, R⁵, and R⁶, independently, are H or CH₃;

10

said method comprising the steps of:


(1) reacting a polyamine of formula:



15

wherein R¹⁰ is a substituted arylsulfonyl protecting
 group;

with an anhydride of formula (ii)




(ii)

or



20

formula (iii)



(iii)

to obtain a naphthalimide of formula



5

(2) removing the protecting group R^{10} from the naphthalimide of step (1) to obtain a deprotected naphthalimide;

- 10 (3) reacting the deprotected naphthalimide of step (2) with an anhydride of formula (ii) or formula (iii), to obtain the compound of formula (i).

R^{10} is a substituted arylsulfonyl protecting group, for example arylsulfonyl groups wherein the aryl group is substituted with 0-5 groups selected independently from: phenyl, benzyl, phenethyl, phenoxy, benzyloxy, halogen, hydroxy, nitro, cyano, C₁-C₅ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkylmethyl, C₇-C₁₀ arylalkyl, C₁-C₄ alkoxy, formyl, C₃-C₆ cycloalkoxy, C₂-C₆ alkoxyalkyl, C₁-C₄ hydroxyalkyl, methylenedioxy, ethylenedioxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₄ alkylcarbonyloxy, C₁-C₄ alkylcarbonyl, C₁-C₄ alkylcarbonylamino.

25

A preferred R^{10} is the mesitylenesulfonyl group.

Further examples of substituted arylsulfonyl protecting groups are described, for example, in Greene

and Wutz, "Protective Groups in Organic Synthesis" John Wiley & Sons, New York (1991) and "The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby
5 incorporated by reference.

As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl. As used herein, "alkyl" is intended to include both branched and
10 straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge.

15 The term "substituted", as used herein, means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.

20 By "stable compound" or "stable structure" is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

25 The compounds of the present invention, although encompassed within the broad scope of U.S. Patent 4,874,863, are not specifically claimed or exemplified therein. Brana et al. do not describe the synthesis of
30 any unsymmetrical bis-naphthalimides. Moreover, the compounds of the present invention were discovered to have significantly increased antitumor activity relative to the compounds specifically disclosed in Brana et al., U.S. Patent 4,874,863. Whereas the compounds of the
35 present invention exhibit very efficacious *in vivo* activity against solid tumors, the structurally similar

compounds specifically disclosed by Brana et al. were found to be inactive.

5 In addition, the bis-naphthalimides of the present invention were found to have increased water solubility relative to certain compounds specifically disclosed by Brana et al.


10 Compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry. The references cited below are all incorporated herein by reference.

15 Compounds of this invention can be synthesized by reacting approximately equimolar amounts of the corresponding anhydrides of formula (ii) and (iii) and polyamine of formula (iv) in a suitable solvent, said solvent being substantially nonreactive with the
20 starting materials and products (i.e., any of the compounds of formula (i), (ii), (iii), or (iv)), at a temperature ranging from ambient to the solvent's boiling temperature (Scheme A). Suitable solvents include but are not limited to, for example, ethanol,
25 DMSO, dimethylformamide, or tetrahydrofuran.

The resulting free base of (i) can be acidified with the appropriate mineral or organic acid in ethanol or dichloromethane, for example, to produce a pharmaceutically acceptable salt. Generally,
30 pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free base form of these compounds with a stoichiometric amount of the appropriate acid in an organic solvent or in water, or in a mixture of the two; generally, nonaqueous media
35 like ether, dichloromethane, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of

suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. The free base of (i) may require purification by techniques such as column chromatography, recrystallation, or distillation for example, as well as other techniques well known to those skilled in the art of organic synthesis before its salt can be prepared as described above.

10

Scheme A

15 The anhydrides (ii) and (iii) are commercially available. Polyamines of formula (iv) can be prepared according to the methods described below.


For example the synthesis of compounds of formula I where $\text{R}^{11}=\text{R}^6=\text{CH}_3$, $\text{R}^{12}=\text{R}^3=\text{R}^4=\text{R}^5=\text{H}$, (see Scheme I) can be accomplished by the reaction of BOC-(D)-alanine with 1,1'-carbonyldiimidazole (CDI) followed by reaction with ethylenediamine under standard conditions to give the diamide II. Acid hydrolysis of the BOC (N-tert-butoxycarbonyl) protecting group, followed by reduction with diborane in refluxing tetrahydrofuran and acidic

25

workup afforded III, which can be neutralized to give the pure free base IV. By treating equimolar amounts of the corresponding anhydrides ii and iii with IV in tetrahydrofuran at reflux temperature, the unsymmetrical freebase Ib is obtained after purification on silica gel. The resulting free base is acidified with an appropriate mineral or organic acid in dichloromethane, for example methanesulfonic acid to produce the pharmaceutically acceptable salt Ia.

Procedures for the synthesis of the diastereomeric or enantiomeric forms of the polyamine linker IV or mixtures of enantiomeric or diastereomeric forms thereof are fully described in commonly assigned, copending patent application USSN 07/805,044, filed December 11, 1991.

Scheme I




20

The compound of formula I can also be synthesized by an alternative process via a stepwise condensation of anhydrides ii and iii onto a differentially protected linker (see scheme II). This procedure commences with the CDI coupling of N-mesitylenesulfonyl-D-alanine (V) (Ger. Patent DE 2544859, 1976) and N-tert-

butoxycarbonyl-1,2-ethanediamine (Krapcho, Syn.Comm. 1990, 20(16), 2559) to yield the amide VI. The BOC protecting group of amide VI was then removed under acidic conditions, and the resulting salt was treated
5 with sodium carbonate to afford the free base VII. This material was then subjected to a CDI coupling with N-BOC-D-alanine, acid removal of the BOC group, and subsequent treatment with sodium carbonate to yield the diamide IX. The amide bonds of IX were reduced with
10 $\text{BH}_3 \cdot \text{THF}$ to provide the key differentially protected linker X which was then condensed with the anhydride ii (or iii) to yield the mono-naphthalimide XI (or XII). At this point, the mesitylenesulfonyl group was removed with 30% HBr/acetic acid to afford the crystalline salt
15 XIII (or XIV). Treatment with sodium carbonate gave the freebase, which was condensed with the appropriate anhydride iii (or ii) to give the freebase Ib. This free base can be acidified with the appropriate mineral or organic acid as described above to produce a
20 pharmaceutically acceptable salt.

Scheme II




5

Bis-naphthalimides of the formula XVI where $\text{R}^{11}=\text{R}^3=\text{R}^4=\text{R}^6=\text{H}$, $\text{R}^{12}=\text{R}^5=\text{CH}_3$ can be made as shown in Scheme III. By reacting equimolar amounts of the corresponding anhydrides of formula (ii) and (iii) with polyamines XV (a-d) in an inert solvent such as ethanol or dimethylformamide or tetrahydrofuran, for example, at a temperature ranging from ambient to the solvent's boiling temperature. The resulting free base of XV can be acidified with the appropriate mineral or organic acid to produce a pharmaceutically acceptable salt. Detailed procedures for the synthesis of the polyamine linkers XV (a-d) are described in commonly assigned,

copending patent application USSN 07/805,044, filed
December 11, 1991.


Scheme III

5



Bis-naphthalimides of the formula XXV where
 $R^{12}=R^5=H$, $R^{11}=R^6=CH_3$, and R^3 or $R^4=CH_3$ can be prepared as
 10 shown in Scheme IV. As before, N-mesitylenesulfonyl-
 alanine V can be homologated under standard conditions
 with ammonia followed by reduction with $BH_3 \cdot THF$ to
 provide the amine XVII. Coupling to BOC-alanine with
 CDI followed by deprotection of the BOC protecting
 15 group, gives the amide XVIII. The linker is completed
 by another BOC-alanine coupling/BOC deprotection
 sequence to provide the diamide XIX. This material can
 then be reduced under the standard borane conditions to
 give the triamine XX. The first naphthalimide can be
 20 condensed onto the primary amine with ii or iii yielding
 the mono-naphthalimide XXI or XXII. Deprotection of the
 mesitylenesulfonyl protecting group with HBr /acetic acid
 can give the primary amine XXIII or XXIV. The synthesis
 can be completed by a second condensation with iii or ii
 25 to yield the desired unsymmetrical bis-naphthalimide XXV
 or XXVI.


Scheme IV



5

- Bis-naphthalimides of the formula XXXIV where
 R¹²=R⁶=H, R¹¹=R⁵=CH₃ and R³ or R⁴=CH₃ can be obtained
 starting from N-mesitylenesulfonyl-alanine (V) (Scheme
 V). Standard CDI coupling of BOC-alanine and V followed
 10 by deprotection of the BOC protecting group gives the
 amide XXVII. Another CDI coupling with alaninamide
 gives the triamide XXVIII. Borane reduction gives the
 differentially protected linker XXIX, which can be
 carried through the naphthalic anhydride condensation-
 15 HBr/acetic acid deprotection-naphthalic anhydride
 condensation sequence to provide the desired
 unsymmetrical bis-naphthalimide XXXIV or XXXV.

Scheme V



5

Bis-naphthalimides of the formula XXXXVI or XXXXVII where R¹¹=R⁶=H, R¹²=R⁵=CH₃ and R³ or R⁴=CH₃ can be made as shown in Scheme VI. The BOC protected diamine XXXVI (PCT patent application WO 8504403 A1) is converted into the mesitylenesulfonyl amine XXXVII under standard conditions. Lactic acid XXXVIII can be converted to the t-butyl ester triflate XXXIX and coupled with XXXVII, using chemistry described by Webb et. al., (J. Org. Chem., p.4706 (1991)) to provide the amine XXXX. BOC deprotection, followed by CDI coupling with alanine methyl ester, and amidation with ammonia can provide the diamide XXXXII. Reduction of the diamide with borane provides the differentially protected polyamine linker XXXXIII. This material can then be taken through the naphthalic anhydride condensation-HBr/acetic acid deprotection-naphthalic anhydride condensation sequence

10


15

20

to provide the desired unsymmetrical bis-naphthalimides XXXXVI or XXXXVII.

Scheme VI

5



The compounds of this invention and their preparation are further understood by the following Example.

Example 1

(R,R)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]isoquinolin-2-(3H)-yl)-propylamino)ethylamino)-1-methylethyl]-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-dione bis-methanesulfonate (Ia)

Method A

Part A: Preparation of the di-BOC protected diamide (II).

5 To a stirred solution of 100 g (528 mmol) of t-BOC-D-alanine in 1500 mL of methylene chloride at 0°C was added 89 g (549 mmol) of 1,1'-carbonyldiimidazole. After stirring 2.5 h, 17.6 mL (263 mmol) of ethylenediamine was added dropwise. After stirring 15
10 min., the suspension was warmed to room temperature and allowed to stir overnight. The mixture was then washed with saturated Na₂CO₃, water, and the organic layer was dried with anhydrous MgSO₄. The solvent was removed under reduced pressure to give 104 g (98%) of II as a
15 white solid. ¹H NMR (300 MHz, CDCl₃) δ 6.83 (broad s, 2H, NH), 5.18 (d, 2H, NH), 4.11 (m, 2H, CH), 3.48 (m, 2H, CH₂), 3.30 (m, 2H, CH₂), 1.44 (s, 18H, t-Bu), 1.35 (d, 6H, CH₃); MS (CI, CH₄) m/e 403 (M+1).

20 Part B: Reduction of II to give the polyamine salt (III).

To a stirred suspension of 51 g (127 mmol) of II in 100 mL of 1,4-dioxane was added 200 mL of a 4 M solution of HCl in 1,4-dioxane. After stirring 4h, the slurry
25 was concentrated under reduced pressure. To the resulting solid 1450 mL of a 1 M solution of BH₃•THF in THF was added and the suspension was refluxed overnight. The solution was then cooled to room temperature and 300 mL of methanol was added dropwise. The solution was
30 refluxed 4 h, cooled to room temperature, concentrated under reduced pressure, and azeotroped with 500 mL of methanol. The resulting solid was then taken up in 500 mL of methanol and 35 mL of 37% aqueous HCl was added. The resulting suspension was heated on a steam bath 15
35 min., cooled to room temperature, and 800 mL of ether was added. The resulting white solid was then collected

on a filter to give 38 g (93%) of III. ^1H NMR (300 MHz, D_2O) δ 3.63 (m, 2H, CH), 3.38 (s, 4H,), 3.24 (m, 4H, CH_2), 1.28 (d, 6H, CH_3); MS (CI, CH_4) m/e 175 (M+1).

5 Part C Neutralization of III to yield the freebase (IV).

To a stirred slurry of 72.3 g (226 mmol) of III in 1450 mL of ethanol, was added 291 g of a 21% solution of sodium ethoxide in ethanol. After stirring 2 h, the
10 mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. Distillation of the crude amine under high vacuum gave 35.5 g (90%) of IV as a colorless oil. ^1H NMR (300 MHz, CDCl_3) δ 2.95 (m, 2H, CH), 2.70 (m, 4H, CH_2), 2.55 (m, 2H, CH_2),
15 2.33 (m, 2H, CH_2), 1.37 (broad s, 6H, NH_2), 1.03 (d, 6H, CH_3); MS (CI, NH_3) m/e 175 (M+1).

Part D: Condensation of IV with the naphthalic anhydrides to give the bis-naphthalimide (I).

20 A solution of 500 mg (2.87 mmol) of IV in 10 mL of THF was added to a slurry of 697 mg (2.87 mmol) of 3-nitro-1,8-naphthalic anhydride and 568 mg (2.87 mmol) of 1,8-naphthalic anhydride in 20 mL of THF. The mixture was refluxed overnight and the dark suspension was
25 cooled to room temperature. The solvent was removed under reduced pressure and the residue was chromatographed on silica gel. Elution with 5% methanol in methylene chloride gave 369 mg (23%) of the freebase Ib as a brown solid. ^1H NMR (300 MHz, CDCl_3) δ 9.20 (s,
30 1H, aromatic), 9.06 (s, 1H, aromatic), 8.68 (d, 1H, aromatic), 8.50 (d, 2H, aromatic), 8.34 (d, 1H, aromatic), 8.16 (d, 2H, aromatic), 7.91 (t, 1H, aromatic), 7.72 (t, 2H, aromatic), 5.25 (m, 2H, CH), 3.43 (m, 2H, CH_2), 2.94 (m, 2H, CH_2), 2.77 (m, 4H, CH_2),
35 2.31 (s, NH), 1.47 (d, 3H, CH_3), 1.42 (d, 3H, CH_3); MS (CI, NH_3) m/e 580 (M+1).

The resulting freebase was converted to the bis-methanesulfonate by treatment with 78 μ L (1.2 mmol) of methanesulfonic acid in 20 mL methylene chloride. After stirring overnight, the solid was collected by
5 filtration to give 392 mg (18%) of Ia as a light tan powder. (mp 194-199°C).

The compound of formula I can also be synthesized by the alternate process described below.

10

Synthesis of I, Method B

Part A: Coupling of the protected diamine to give the amide (VI).

15 Mesitylenesulfonyl-D-alanine V (39.7 g, 140 mmol) was dissolved in 500 mL of methylene chloride and cooled to 0°C prior to the addition of CDI (25.8 g, 160 mmol). After 2 h at 0°C, N-tert-butoxycarbonyl-1,2-ethanediamine (21.3 g, 130 mmol) in 10 mL of methylene
20 chloride was added. The solution warmed to room temperature and stirred 12 h. The solution was then washed with saturated Na₂CO₃, H₂O, and 2% HCl. The methylene chloride was dried with anhydrous MgSO₄ and concentrated under reduced pressure to give 43.3 g (80%)
25 of the amide VI as a white foam. ¹H-NMR (300 MHz, CDCl₃) δ 6.96 (s, 2H, aromatic), 6.90 (broad s, 1H, NH), 5.65 (broad d, 1H, NH), 5.05 (broad s, 1H, NH), 3.67 (m, 1H, CH), 3.22 (m, 4H, CH₂), 2.63 (s, 6H, CH₃), 2.30 (s, 3H, CH₃), 1.43 (s, 9H, CH₂), 1.26 (d, 3H, CH₃); MS
30 (CI, NH₃) m/e 414 (M+1).

Part B: Deprotection and neutralization to give the freebase (VII).

35 The amide VI (60.3 g, 146 mmol) was dissolved in 150 mL of dioxane and cooled in a ice bath prior to the addition of 210 mL (840 mmol) of a 4 M solution of HCl

in dioxane. The solution was warmed to room temperature and stirred for 4 h. The solvent was then removed under reduced pressure to give a solid, which was dissolved in 300 mL of saturated Na_2CO_3 and extracted with methylene chloride. The methylene chloride was dried with Na_2CO_3 and was concentrated under reduced pressure to give 37.6 g (89%) of the free base VII as a white foam. $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 7.06 (m, 1H, 1 NH), 6.95 (s, 2H, aromatic), 3.68-3.57 (m, 1H), 3.26 (m, 2H, CH_2), 2.79 (t, 2H, CH_2), 2.62 (s, 6H, 2 CH_3), 2.30 (s, 3H, 1 CH_3), 1.22 (d, 3H, 1 CH_3); MS (CI, NH_3) m/e 314 (M+1).

Part C: Coupling to give the diamide (VIII).

The protected amino acid N-BOC-D-Ala (22.9 g, 120 mmol) was dissolved in 400 mL of methylene chloride and cooled to 0°C prior to the addition of CDI (19.6 g, 120 mmol). The resulting mixture stirred 2 h at 0°C before the amine VII (35.4 g, 110 mmol) suspended in 200 mL of methylene chloride was added dropwise. This mixture then warmed to room temperature and stirred 15 h. The solution was then washed with saturated Na_2CO_3 , H_2O , and 2% HCl. The methylene chloride was dried with anhydrous MgSO_4 and concentrated under reduced pressure to give 41.2 g of the diamide VIII as a white foam. $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 7.14 (broad s, 1H, NH), 6.96 (s, 2H, aromatic), 6.83 (broad s, 1H, NH), 5.92 (broad s, 1H, NH), 5.31 (broad s, 1H, NH), 4.10 (m, 1H, CH), 3.71 (m, 1H, CH), 3.4-3.2 (m, 2H, CH_2), 2.63 (s, 6H, CH_3), 2.30 (s, 3H, CH_3), 1.43 (s, 9H, CH_3), 1.22 (d, 3H, CH_3); MS (CI, NH_3) m/e 485 (M+1).

Part D: Deprotection and neutralization of the BOC protected amine to give IX.

The diamide VIII (41.2 g, 85 mmol) was dissolved in 10 mL of dioxane and cooled in an ice bath prior to the addition of 129 mL (510 mmol) of a 4 M solution of HCl

in dioxane. The solution was warmed to room temperature and stirred for 4 h. The solvent was then removed to give a solid, which was dissolved in 300 mL of saturated Na_2CO_3 and extracted with methylene chloride. The

5 methylene chloride was dried with Na_2CO_3 and concentrated under reduced pressure to give 22.8 g (70%) of the free base IX as a white solid. $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 7.68 (broad m, 1H, NH), 7.18 (broad m, 1H, NH), 6.96 (s, 2H, aromatic), 3.66 (m, 1H), 3.50-3.25 (m, 5H),

10 2.63 (s, 6H, CH_3), 2.3 (s, 3H, CH_3), 1.31 (d, 3H, CH_3), 1.23 (d, 3H, CH_3); MS (CI, NH_3); m/e 385 (M+1).

Part E: Reduction to give the polyamine (X).

The free amine IX (22.8 g, 59.4 mmol) was dissolved

15 in 200 mL of THF prior to the addition of 1M $\text{BH}_3 \cdot \text{THF}$ (594 mL, 594 mmol). This solution was refluxed for 15 h. After cooling, 200 mL of methanol was added, and the solution was refluxed an additional 4 h. The solution was then cooled and concentrated under reduced pressure.

20 The resulting residue was dissolved in 150 mL of MeOH and cooled to 0°C prior to the addition of 6 mL of concentrated HCl. This solution was concentrated under reduced pressure to a white solid, which was dissolved in saturated Na_2CO_3 and extracted with methylene

25 chloride. The methylene chloride was dried with Na_2CO_3 , and concentrated under reduced pressure to give 22.1 g (93%) of the free base X as a white foam. $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 6.94 (s, 2H, aromatic), 3.63 (t, 1H), 3.23-3.17 (m, 1H), 2.99-2.93 (m, 1H), 2.68-2.3 (m, 8H),

30 2.66 (s, 6H, CH_3), 2.29 (s, 3H, CH_3), 1.6-1.5 (m, 1H), 1.43-1.3 (m, 1H), 1.06 (t, 6H, CH_3), 0.92 (t, 1H); MS (CI, NH_3) m/e 357 (M+1).

Part F: Condensation to give the mono-imide (XI).

35 The amine X (22.1 g, 55.4 mmol) was dissolved in 500 mL of THF prior to the addition of 3-nitro-

naphthalic anhydride (12.0 g, 49.5 mmol), and the resulting solution was refluxed 17 h. After cooling, the solution was concentrated under reduced pressure to an oil. Flash chromatography on silica gel provided
5 19.3 g (66%) of the imide XI as a foam. $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 9.24 (d, 1H, aromatic), 9.06 (d, 1H, aromatic), 8.73 (d, 1H, aromatic), 8.38 (d, 1H, aromatic), 7.91 (t, 1H, aromatic), 6.88 (s, 2H, aromatic), 5.4 (m, 1H, CH), 3.59 (m, 1H, CH), 3.12 (m,
10 1H, CH), 3.01 (m, 1H, CH), 2.82 (m, 1H, CH), 2.70 (m, 1H, CH), 2.56-2.45 (m, 4H, CH_2), 2.52 (s, 6H, CH_3), 2.27 (d, 3H, CH_3), 1.58 (d, 3H, CH_3), 0.92 (d, 3H, CH_3); MS (CI, NH_3) m/e 582 (M+1).

15 Part G: Deprotection of the mesitylenesulfonyl group to give the amine XIII.

The imide XI (13.2 g, 22.7 mmol) was dissolved in 250 mL of 30% HBr/acetic acid prior to the addition of
20 phenol (10.7 g, 113.5 mmol). This solution was heated at reflux for 4 h and then stirred at room temperature for 12 h. The solution was cooled to 0°C and 300 mL of ether was added. The resulting solid was filtered and washed with ether to provide 12.3 g (84 %) of the tri-
25 hydrogen bromide salt XIII as a solid. m.p. $253^\circ\text{--}254^\circ\text{C}$; $^1\text{H-NMR}$ (D_2O) δ 8.90 (d, 1H, 1 aromatic), 8.78 (d, 1H, aromatic), 8.50 (d, 1H, aromatic), 8.28 (d, 1H, aromatic), 7.76 (t, 1H, aromatic), 5.46 (m, 1H, CH),
3.90 (m, 1H), 3.64 (m, 1H), 3.5-3.18 (m, 7H), 1.56 (d,
30 3H, CH_3) and 1.27 (d, 3H, CH_3); MS (CI, NH_3) m/e 400 (free base) (M+1).

Part H: Condensation to give the bis-naphthalimide (I).

The tri-hydrogen bromide salt XIII (74.1 mg, 0.1
35 mmol) was dissolved in 5 mL of saturated Na_2CO_3 and extracted with methylene chloride. The methylene

chloride was dried with Na_2CO_3 , filtered, and concentrated in vacuo to give the free base. This free base was dissolved in 2 mL of THF prior to the addition of 1,8-naphthalic anhydride (19.8 mg, 0.1 mmol), and the resulting solution was refluxed 15 h. After cooling, the solution was concentrated to a crude oil. Flash chromatography on silica gel provided 40.3 mg (62%) of the freebase Ib. The freebase can be converted to the title compound (Ia) as described above in reference to Scheme A.

Utility

In vitro Growth Inhibitory Activity

15

L1210 cells were maintained in RPMI-1640 a medium supplemented with 10% heat inactivated fetal bovine serum and 50 mL mercaptoethanol/liter medium (RPMI-L). B16 cells were maintained in RPMI-1640 medium supplemented with 15% heat inactivated fetal bovine serum and antibiotics (RPMI-C).

Exponentially growing murine leukemia L1210 cells (1×10^3 cells) in 0.1 mL medium were seeded on day 0 in a 96-well microtiter plate. On day 1, 0.1 μL aliquot of medium containing graded concentrations of test analogs was added to the initial volume. After incubation at 37°C in a humidified incubator for 3 days, the plates were centrifuged briefly and 100 μL of the growth medium was removed.

Exponentially growing human colon Clone A cells (8×10^2) in 0.1 mL medium were seeded on day 0 in a 96-well microtiter plate. On day 1, 0.1 mL of medium containing graded concentrations of test analogs was added to the initial volume. After incubation at 37°C in a humidified incubator for 6 days, the plates were

centrifuged briefly and 0.1 mL of the growth medium was removed.

5 The cell cultures (above) were then incubated with
50 μ L of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; 1 mg/ml in Dulbecco's
phosphate buffer saline) for 4 hours at 37°C. The
resulting purple formazan precipitate was solubilized
with 200 μ L of 0.04 N HCl in isopropyl alcohol.
10 Absorbance was read in a Titertek Multiskan MCC scanning
well spectrophotometer (Flow Laboratories) at a test
wavelength of 570 nm and a reference wavelength of 630
nm.

 The ID₅₀ values were determined by a computer
15 program that fit all of the data (8 determinations per
concentration and 12 concentrations per test analog) to
the following equation:

$$Y = ((A_m - A_o) / (1 + (X / ID_{50})^n)) + A_o$$

 where: A_m = absorbance of the control cells; A_o =
20 absorbance of the cells in the presence of highest drug
concentration; Y = observed absorbance; X = drug
concentration; ID₅₀ = dose of drug that inhibits the
growth of cells to one half that of the control cells.

25 Results of the *in vitro* L1210 leukemia and Clone A
colon carcinoma growth inhibition testing show that a
representative compound of the invention, the compound
of Example 1, has an ID₅₀ of 0.1 μ g/mL and 0.0036 μ g/mL,
respectively.

30

In Vivo Tumor Models

 Example 1, a representative compound of the present
invention, has been tested in pre-clinical tests of
35 anti-cancer activity which are indicative of clinical
utility. The potent (<0.1 μ g/mL) growth inhibitory

activity against L1210 leukemia and Clone A colon carcinoma cell lines suggest that the compounds of the invention have the potential to be active in *in vivo* models. This was confirmed, since the presently claimed
5 compound showed striking *in vivo* efficacy against human tumors xenografted in nude mice.

The methods used in the testing of compounds in the *in vivo* human tumor xenograft models are described below.

10

In Vivo Human Tumor Xenograft Models

The MX-1 human mammary carcinoma and the DLD-2 human colon carcinoma were originally obtained from a
15 surgically removed primary breast tumor and colon carcinoma, respectively. The human tumor lines were maintained by serial passage in athymic nude mice. The MX-1 human mammary carcinoma is an established tumor used by the NCI. The MX-1 and DLD-2 tumor models have
20 been well characterized.

The mice used in these experiments were outbred Swiss mice or BALB/c mice bearing the nude (*nu/nu*) gene. On day 0 male and female mice weighing 22-30 g are inoculated with 0.2 mL of a 25% tumor mince. This mince
25 is prepared by mincing fresh tumor tissue, grown subcutaneously in passage mice, in sterile physiological saline. Palpable tumors weighing approximately 50 mg appear in the mice within 7-10 days after inoculation. The mice are pair matched by tumor weight and sex into
30 groups of ten each and the test compounds and vehicle control are administered intravenously (*i.v.*) once daily for nine consecutive days. A >20% decrease in body weight on day 5 following compound administration is considered an indication of toxicity. Tumor measurements
35 and body weights are recorded once a week. Fifteen to

18 days after the initial injection the mice are weighed, sacrificed and the tumors excised and weighed.

The efficacy of the test compounds is determined by the extent of tumor growth inhibition in treated versus vehicle-treated control mice. Initial tumor weights (mg) are calculated from the tumor dimensions (mm) measured from caliper measurements, using the formula for a prolate ellipsoid (mg of tumor weight = (length x width²)/2). Net tumor weights are calculated for each of the treated groups and the vehicle-treated control group by subtracting the initial tumor weight from the final tumor weight on day 15. Results are expressed as a percentage decrease relative to the mean tumor weight for the control vehicle-treated group.

$$\% \text{ Tumor Growth Inhibition} = \left[1 - \frac{\text{mean tumor weight of treated}}{\text{mean tumor weight of control}} \right] \times 100$$

Activity Criteria

20

The criteria of the National Cancer Institute (NCI) for activity in the *in vivo* cancer models were used. Actual tumor regressions (IR = incomplete regression; FR = full regression) indicate excellent to outstanding activity. Tumor growth inhibition of ≥90% in the DLD-2 assay is considered good to excellent and inhibition of 58-89% is considered moderate. Compounds demonstrating <58% growth inhibition are considered inactive.

30

The compound of Example 1 exhibited excellent to outstanding activity in the MX-1 human breast tumor model. In addition, the compound of Example 1 exhibited excellent to outstanding activity in the DLD-2 human

colon tumor model. All of the compounds of the invention are expected to exhibit similar activity.

5 The demonstrated effectiveness of the compounds of
the present invention in the human breast and colon
tumor xenograft models indicate that the compounds of
the present invention may be useful for the treatment of
solid tumors in man, and, in particular, tumors of the
breast and colon. This conclusion is further supported
10 by published analyses correlating pre-clinical test
results with clinical efficacy of anti-cancer agents.
For example, see: Goldin and Venditti (1980) Recent
Results Cancer Research 76: 176-191; Goldin et al.
(1981) Eur. J. Cancer 17: 129-142; Mattern et al. (1988)
15 Cancer and Metastasis Review 7: 263-284; Jackson et al.
(1990) Cancer Investigations 8: 39-47. Based on these
published analyses, the exceptional high level of
antitumor activity exhibited by the presently claimed
compounds provide strong evidence that the compounds
20 claimed in present invention may have important
therapeutic utility in the treatment of cancer in man.

Dosage and Formulation

25 The antitumor compounds (active ingredients) of
this invention can be administered to inhibit tumors by
any means that produces contact of the active ingredient
with the agent's site of action in the body of a mammal.
30 They can be administered by any conventional means
available for use in conjunction with pharmaceuticals,
either as individual therapeutic active ingredients or
in a combination of therapeutic active ingredients.
They can be administered alone, but are generally
35 administered with a pharmaceutical carrier selected on

the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will be a tumor-inhibiting amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment, and the effect desired. Usually a daily dosage of active ingredient can be about 1 to 400 milligrams per kilogram of body weight. Ordinarily, 10 to 200, and preferably 10 to 50, milligrams per kilogram per day given in divided doses 2 to 4 times a day or in sustained release form is effective to obtain desired results.

Dosage forms (compositions) suitable for internal administration contain from about 1.0 milligram to about 500 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and

protect the tablet from the atmosphere or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid either alone or combined are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.

Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.

Capsules: Capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 175 milligrams of lactose, 24 milligrams of talc, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules: A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft

gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.

Tablets: Tablets are prepared by conventional
5 procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of cornstarch and 98 milligrams of lactose. Appropriate
10 coatings may be applied to increase palatability or delay absorption.

Injectable: A parenteral composition suitable for administration by injection is prepared by stirring 1.5%
15 by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.


Suspension: An aqueous suspension is prepared for
20 oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.
25

In the present disclosure it should be understood that the specified materials and conditions are important in practicing the invention but that unspecified materials and conditions are not excluded so
30 long as they do not prevent the benefits of the invention from being realized.

CLAIMS

WHAT IS CLAIMED IS:

- 5 1. A compound having the formula (i):



(i)

- 10 or enantiomeric or diastereomeric forms thereof, or mixtures of enantiomeric or diastereomeric forms thereof, and pharmaceutically acceptable salts thereof, wherein:

- 15 R¹¹, R¹², R³, R⁴, R⁵, and R⁶, independently, are H or CH₃.

2. A compound of Claim 1 wherein:

R¹¹ and R⁶ are CH₃; and

- 20 R¹², R³, R⁴, and R⁵ are H.

3. A compound of Claim 2 selected from the following compounds, and pharmaceutically acceptable salts thereof:

25 (R,R)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-dione;

30

(S,S)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione;

5

(racemate + meso)-2-{2-[2-((2-(1,3-Dioxo-1H-
benz[de]-isoquinolin-2-(3H)-yl)-
propylamino))ethylamino]-1-methylethyl}-5-nitro-1H-
benz[de]isoquinolin-1,3-(2H)-dione; and

10

(meso)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione.

15

4. A compound of Claim 2 selected from the group
consisting of:

(R,R)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione bis-methanesulfonate;

20

(S,S)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-
methylethyl}-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione bis-methanesulfonate;

25

(racemate + meso)-2-{2-[2-((2-(1,3-Dioxo-1H-
benz[de]-isoquinolin-2-(3H)-yl)-
propylamino))ethylamino]-1-methylethyl}-5-nitro-1H-
benz[de]isoquinolin-1,3-(2H)-dione bis-methanesulfonate;
and

30

(meso)-2-{2-[2-((2-(1,3-Dioxo-1H-benz[de]-
isoquinolin-2-(3H)-yl)-propylamino))ethylamino]-1-

35

methylethyl)-5-nitro-1H-benz[de]isoquinolin-1,3-(2H)-
dione bis-methanesulfonate.

5 5. A pharmaceutical composition comprising a
therapeutically effective amount of a compound of Claim
1 and a pharmaceutical carrier.

10 6. A pharmaceutical composition comprising a
therapeutically effective amount of a compound of Claim
2 and a pharmaceutical carrier.

15 7. A pharmaceutical composition comprising a
therapeutically effective amount of a compound of Claim
3 and a pharmaceutical carrier.

8. A pharmaceutical composition comprising a
therapeutically effective amount of a compound of Claim
4 and a pharmaceutical carrier.


20 9. A method of treating a colon tumor in a mammal
comprising administering to a mammal bearing such a
tumor, a tumor-inhibiting amount of a compound of Claim
1.

25 10. A method of treating a breast tumor in a
mammal comprising administering to a mammal bearing such
a tumor, a tumor-inhibiting amount of a compound of
Claim 1.

30 11. A process for the preparation of a compound
having the formula (i):

in a suitable solvent, said solvent being substantially nonreactive with the compounds of formula (i), (ii), (iii), or (iv), at a temperature ranging from ambient to the solvent's boiling temperature, for a time sufficient to obtain the compound of formula (i).

12. A method of preparing a compound having the formula (i):




or enantiomeric or diastereomeric forms thereof, or mixtures of enantiomeric or diastereomeric forms thereof, and pharmaceutically acceptable salts thereof, wherein:

R¹¹, R¹², R³, R⁴, R⁵, and R⁶, independently, are H or CH₃;


20 said method comprising the steps of:

(1) reacting a polyamine of formula:



25 wherein R¹⁰ is a substituted arylsulfonyl protecting group;

with an anhydride of formula (ii)




(i)

or enantiomeric or diastereomeric forms thereof, or
 5 mixtures of enantiomeric or diastereomeric forms
 thereof, and pharmaceutically acceptable salts thereof,
 wherein:

R¹¹, R¹², R³, R⁴, R⁵, and R⁶, independently, are H or CH₃;

10


said process comprising contacting equimolar amounts of:
 an anhydride of formula (ii)



(ii) ;


15

an anhydride of formula (iii)




(iii) ; and

a polyamine of formula (iv)




(iv) ;



20



formula (iii)



5 to obtain a naphthalimide of formula



10 (2) removing the protecting group R^{10} from the naphthalimide of step (1) to obtain a deprotected naphthalimide;

15 (3) reacting the deprotected naphthalimide of step (2) with an anhydride of formula (ii) or formula (iii), to obtain the compound of formula (i).

INTERNATIONAL SEARCH REPORT

PCT/US 93/06771

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D221/14; A61K31/435

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

C07D

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0 281 902 (KNOLL AG) 14 September 1988 see claims & US,A,4 874 863 cited in the application ---	1,5-10
A	US,A,4 146 720 (LABORATORIOS MADE S.A.) 27 March 1979 see column 2, line 65 - column 4, line 35; claim 1 ---	1,5-10
P,X	WO,A,9 217 453 (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 15 October 1992 *pages 2-4,13,14,32-41* -----	1,5-12

¹⁰ Special categories of cited documents:¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance¹⁰ "E" earlier document but published on or after the international filing date¹⁰ "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)¹⁰ "O" document referring to an oral disclosure, use, exhibition or other means¹⁰ "P" document published prior to the international filing date but later than the priority date claimed¹⁰ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention¹⁰ "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step¹⁰ "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.¹⁰ "A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

30 SEPTEMBER 1993

Date of Mailing of this International Search Report

- 7. 10. 93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

HENRY J.C.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/06771

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 9 and 10 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9306771
SA 76935

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30/09/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0281902	14-09-88	DE-A- 3707651	22-09-88
		DE-A- 3881544	15-07-93
		JP-A- 63230671	27-09-88
		US-A- 4874863	17-10-89

US-A-4146720	27-03-79	None	

WO-A-9217453	15-10-92	US-A- 5206249	27-04-93
		AU-A- 1767692	02-11-92
		EP-A- 0506008	30-09-92

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☒ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.